Oral squamous cell carcinomas (OSCCs) are invasive epithelial neoplasm with various degree of squamous differentiation and penchant for early and extensive metastases into the lymph nodes. They are predominantly present in middle-aged people (the fifth and sixth decades) who consume alcohol and tobacco. Their origin is squamous epithelium and epidermal keratinocytes, and the most prevalent sites for OSCC are lips, mouth, tongue, salivary glands, gums, oropharynx, and other places within the oral cavity. OSCC represent about 90-95% of mouth cancers, while the remaining 5-10% of malignant tumors are tumors of minor salivary glands, malignant melanomas and soft tissue sarcomas. OSCC mainly occur in people older than 50 years, and rarely in younger than 40 years (1-6%), although the trend observed in recent years shows an increased incidence of cancer in much younger age. They are two to three times more common in men than in women, and the occurrence of disease so far has been mostly associated with smoking and regular alcohol consumption. The etiological factors also include certain viruses, UV radiation, genetic factors, and others [1, 2, 3] .
INTRODUCTION
Oral squamous cell carcinomas (OSCCs) are invasive epithelial neoplasm with various degree of squamous differentiation and penchant for early and extensive metastases into the lymph nodes. They are predominantly present in middle-aged people (the fifth and sixth decades) who consume alcohol and tobacco. Their origin is squamous epithelium and epidermal keratinocytes, and the most prevalent sites for OSCC are lips, mouth, tongue, salivary glands, gums, oropharynx, and other places within the oral cavity. OSCC represent about 90-95% of mouth cancers, while the remaining 5-10% of malignant tumors are tumors of minor salivary glands, malignant melanomas and soft tissue sarcomas. OSCC mainly occur in people older than 50 years, and rarely in younger than 40 years (1-6%), although the trend observed in recent years shows an increased incidence of cancer in much younger age. They are two to three times more common in men than in women, and the occurrence of disease so far has been mostly associated with smoking and regular alcohol consumption. The etiological factors also include certain viruses, UV radiation, genetic factors, and others [1, 2, 3] .
Rapid growth and propensity for metastasis, as well as five-year survival rate of only 34% in case of present metastases make oral cancer one of the major sociomedical problems. Great intellectual efforts and financial resources are invested in tumor research in order to achieve better understanding of their biology that will lead to precise and accurate diagnosis and prediction of patient response to the treatment. Very important research in the field of molecular biology is developing in different directions (some will be mentioned later), important studies are related to genetics and epigenetics. From the aspect of molecular biology, neoplastic transformation is a multistage process of tissue homeostasis disturbance leading to uncontrolled cell proliferation and inhibition of cell death by apoptosis. Each level is characterized by genetic and epigenetic changes and their progressive accumulation lead to transformation of normal cell into malignant.
GENETIC BASIS OF OSCC
Cell division is precisely controlled by genes whose protein products constitute the complex network responsible for receiving, transmitting and final realization of signal for mitosis. The expansion of clone or cell mass is manifested at clinical level as neoplasia and it is caused by structural and functional lesions of specific genetic loci, called "carcinogenic genes". Two key groups of genes that, according to their characteristics, deserve this epithet are: a) oncogenes or mutated forms of normal cellular genes, protooncogenes, present in most eukaryotic genomes; and b) tumor-suppressor genes -anti-oncogenes or inhibitors of uncontrolled growth and proliferation of cells, and thus the malignant phenotype. There are also genes responsible for the correction of endogenously and/or exogenously induced lesions in genetic material -DNA rapper genes or genes that present the first line for defense of human genome integrity, but they will not be the subject of this paper [4] [5] [6] [7] .
Cell homeostasis is maintained by the balance that exists between these two classes of genes. With concurrent activation of oncogenes and inactivation of tumor suppressor genes this homeostasis is violated and tumors are developing. From the perspective of the mechanism of pathogenesis and possible therapeutic interventions, it is important to determine the time and the gene activated/ inactivated in the process of malignant transformation.
Oncogenes
Oncogenes are genes whose protein products stimulate cell growth, division and differentiation through the process of signaling for transduction and transcription regulatory mechanism (Figure 1 ). In the form of proto-oncogenes (regular, non-mutated) they show strictly controlled temporal and spatial expression. The mutation of protooncogenes gives oncogenes, which are uncontrollably expressed. These mutations may include: point mutations, gene deletions, gene amplification and chromosome rearrangements (mainly translocations).
Some of the oncogenes that have proven the role in the pathogenesis of OSCC are H-ras, c-myc and c-erbB-2. They are the key players in one of the central cell signaling paths that lead to uncontrolled proliferation ( Figure 2) .
By position and function, the protein products of the family genes ras (H, K, N) belong to the group of membrane G-proteins, which are spatial and functional connection between the receptors that receive the mitose signal and cytoplasmic protein kinase to which it is transmitted. The frequency of H-ras mutations in OSCC varies and ranges from 5% in Western countries up to 35% in Asian population. In our population, the frequency of H-ras mutation is 22% [8] , provided that in the subgroup of patients who have vermilion cancer, the percentage is even higher (55%). It is interpreted by the synergism of three risk factors-tobacco, alcohol and UV radiation [9] . It is also believed that mutations in H-ras gene are an early event in the development of oral as well as head and neck tumors because they are observed even in some premalignant lesions [10, 11] .
Protein product of c-erbB-2 gene is a transmembrane protein that is also involved in the genesis of proliferative signals from the plasma membrane to the nucleus. Oncogenic activation of c-erbB-2 gene occurs most frequently due to increase in its copy, ie. gene amplification, which results in activation of transmembrane oncoprotein, and the initiation of proliferative signals in the absence of growth factors. Activation of c-erbB-2 oncogene leads to immortalization and transformation of cells in vitro and was also detected in different human tumors. In OSCC, data obtained for alterations in c-erbB-2 gene, depending on the applied methods, range from 20% to 80% [12, 13] . In our patients with OSCC, in 45% of cases, mutation was present in c-erbB-2 gene, of which 32% were amplifications and 13% deletions [8] . Random increase or decrease of the number of gene copies indicates the presence of genomic instability which is a key phenomenon in the pathogenesis of tumor [11] . Regardless of some controversy, most authors think that c-erbB-2 gene has a role in the advanced stage of disease. Expression of c-myc gene is also changed in various human malignancies. Protein product of this gene is a DNA-binding, nuclear protein that modulates the activity of multiple genes involved in processes of cell cycle. Therefore, as a transcription factor, it achieves regulatory activities in the important processes such as stimulation of proliferation, inhibition of differentiation and increased sensitivity to the apoptotic stimuli [14] . Based on available data from the literature, c-myc amplification is found in 20 to 40% of oral cancers in Europe and America, and data for our population fit into these numbers while in Asia this percentage is close to 70% [8, 15, 16] . Similarly to c-erb oncogene, c-myc is frequently mutated (amplified) in tumors of higher histological grade, poorly differentiated and those with metastasis.
Tumor-suppressor genes
Tumor-suppressor genes (anti-oncogenes) are genes which protein products inhibit neoplastic transformation, by preventing cell division if there is damage of the genetic material. They are involved in cell cycle control, by preventing progression through the cell cycle until the damage is repaired, and if damages are extensive, they lead to activation of programmed cell death-apoptosis. Mutations in tumor suppressor genes result in disruption of cell cycle control.
The most important gene in this group is the TP53 gene. Maintaining stability and integrity of the cell genome is the basic biological function of TP53 gene and TP53 protein. According to the literature, this protein is a key transcription factor or biomolecule that restrains division of the cell with damaged genetic material by its regulatory activity ( Figure 2 ). It is also a gene commonly mutated in many human tumors-almost 70% of human solid tumors [17] . Numerous studies show that frequency of mutations in this gene in cancers of the head and neck is about 60% in Europe and America. It is much lower in Asian population and is associated to different lifestyle [18] . Data obtained for our patients with OSCC are in compliance with the date from literature for the western population (60%) [8, 19] . In our patients, the inactivation of TP53 caused by mutations increases with the progression of the disease. Therefore, the frequency of mutations is higher in moderately and poorly differentiated tumors (G2 and G3) compared to well differentiated (G1), as well as in more invasive (T3 and T34) as compared to less invasive (T1 and T2) [20] . Numerous studies from different geographic regions also found a correlation between the presence of TP53 mutations and tobacco consumption, but in our population, this relationship is not confirmed. Beside TP53, the changes in other tumor suppressor genes, such ash Rb and p16 are associated to OSCC [21] .
VIRUSES AND THE PATHOGENESIS OF OSCC
Viral infections and infections with oncogenic types of human papilloma virus (HPV16 and HPV18) which role in development of cervical cancer has been known for long time recently become associated to the pathogenesis of OSCC. It is interesting to mention that HPV positive and HPV negative tumors are considered as different clinical entities. An important mechanism of action of HPV is that the products of viral genome, E6 and E7 oncoproteins, The extreme disparity in world's literature data about the importance of HPV infection in the pathogenesis of OSCC has led researchers to propose two etiopathogenetic mechanisms: HPV+ and HPV-. Head and neck cancers, where viruses were detected in, did not show mutations in tumor suppressor genes (TP53, Rb, etc.) (or extremely rarely) meaning that the loss of function of tumor suppressor resulted from the interaction with viral oncoproteins, and not as the consequence of mutation. It is interesting that the data even at the level of our population is contradictory. One study found a low prevalence of HPV infection in OSCC in Serbia and believes that the predominant route of carcinogenesis is HPV- [8] , while the other study found high incidence of HPV infections [23] .
THE ROLE OF METHYLATION
DNA methylation is an epigenetic mechanism for negative regulation of transcription and gene expression (gene silencing), which was recently considered in carcinogenesis. The correct form of DNA methylation is necessary prerequisite for normal cell functioning. Interfering with the usual pattern of DNA, methylation can cause changes in important cellular mechanisms, such as control of cell cycle, DNA repair, drug resistance, apoptosis and angiogenesis. Disturbed pattern of methylation is one of the characteristics of tumor cells. A large number of human diseases is associated with aberrant DNA methylation. The latest data show the importance of the phenomenon of global methylation in early stages of oral carcinogenesis, one that includes HPV infection as well as carcinogenesis caused by tobacco and alcohol and independent of HPV [24] . In our population hipermethylation of key tumor suppressor genes (p16, DAPK, APC, etc.) was studied and the conclusion was that aberrant methylation is common in OSCC [25] .
PREDISPOSITION FOR THE DEVELOPMENT OSCC
"Carcinogenic genes" and somatic changes in tumor tissue were subjects of numerous studies for many years. Recently, an attention has been brought to the studies on genetic constitution of individuals in attempt to find elements that make someone more or less prone to certain diseases, including OSCC. The differences that exist within a particular DNA locus between individuals of one species are designated as DNA polymorphisms and include polymorphic nucleotide sequence and polymorphism in the length of sequence. Polymorphisms in nucleotide sequences may be related to variability in base substitution and these are dot polymorphisms (SNP) or linked to insertion or deletion of a sequence of nucleotides. Functional polymorphisms affect the expression of genes they are located in, and it is expected to reflect the function of a given protein/enzyme and processes these enzymes are involved in. Association studies are used to assess the presence of gene polymorphisms with the occurrence of disease. This analysis is based on comparison of the frequency of a given polymorphism in the population of affected individuals with the appropriate frequency of polymorphism in a population of healthy people. Some polymorphisms have proved to be useful markers in determining risk of developing disease, its course and response to therapy.
Polymorphisms, such as functional polymorphisms in genes that control cell proliferation and cell death, DNA repair systems, and others are generally accepted as modulators of carcinogenic risk. As a potential markers in susceptibility for the development of OSCC, polymorphisms in genes responsible for inflammatory reactions (genes for cytokines), metabolism of xenobiotics, detoxification (glutathione transferase genes) etc. are also interesting [26] [27] [28] [29] . 
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UVOD
Oral ni skva mo ce lu lar ni kar ci no mi (OSCK) su in va ziv ne epitel ne neo pla zme s raz li či tim ste pe nom skva mo zne di fe ren ci jaci je i sklo no šću ka ra nim i eks ten ziv nim me ta sta za ma u limfne čvo ro ve. Pre te žno se raz vi ja ju kod sre do več nih oso ba koje kon zu mi ra ju al ko hol na pi ća i pu še. Potiču od plo ča sto-sloje vi tog epi te la, od no sno epi derm nih ke ra ti no ci ta, a pre di lek cio no me sto na stan ka su usne, pod usne du plje, je zik, plju vač ne žle zde, de sni, oro fa rinks i dru ga me sta u usti ma. Či ne 90-95% kan ce ra usne du plje, dok su pre o sta lih 5-10% ma lig ni tu mo ri ma lih plju vač nih žle zda, ma lig ni me la no mi i sar ko mi me kih tki va. OSCK se uglav nom ja vlja ju kod oso ba sta ri jih od 50 godi na, ret ko kod mla dih lju di (1-6%), iako se po sled njih go di na za pa ža ten den ci ja če šće po ja ve ovih kar ci no ma i u znat no mlađem ži vot nom do bu. Dva-tri pu ta su če šći kod mu ška ra ca nego kod že na, a po ja va ovih tu mo ra do sad je naj če šće po ve zi vana s pu še njem i sva ko dnev nim kon zu mi ra njem al ko hol nih pića. U eti o lo ške fak to re ubra ja ju se i po je di ni vi ru si, UV zra če-nje, ge ne tič ki fak to ri i dru go [1, 2, 3] . Zbog br zog ra sta i sklo no sti tu mo ra ka me ta sta zi ra nju, kao i pe to go di šnje sto pe pre ži vlja va nja bo le sni ka s me ta sta za ma od sve ga 34%, OSCK su zna ča jan so ci o me di cin ski pro blem. Ve liki in te lek tu al ni na po ri i ma te ri jal na sred stva ula žu se u is tra ži-va nja ovih tu mo ra, ka ko bi se što bo lje sa gle da la nji ho va pri roda, ko ja će vo di ti po sta vlja nju pre ci zne di jag no ze, da va nju pou zda ne prog no ze i pred vi đa nju od go vo ra bo le sni ka na le če nje. Po seb ne na de se po la žu u is tra ži va nja na po lju mo le ku lar ne bio lo gi je, ko ja se raz vi ja ju u raz li či tim prav ci ma, od ko jih će bi ti po me nu ta prevashodno ona ko ja se od no se na ge ne ti ku i epi gene ti ku. S aspek ta mo le ku lar ne bi o lo gi je, neo pla stič na tran sforma ci ja je vi še ste pe ni pro ces na ru ša va nja tkiv ne ho me o sta ze u prav cu ne kon tro li sa ne pro li fe ra ci je će li ja i in hi bi ci je umi ra nja će li ja apop to zom. Sva ki ste pen obe le ža va ju ge ne tič ke i epi gene tič ke iz me ne, a nji ho va pro gre siv na aku mu la ci ja do vo di do tran sfor ma ci je nor mal ne će li je u ma lig nu.
GENETIČKA OSNOVA OSCK
Pre ci zna kon tro la de o be će li ja ostva ru je se po sred stvom ge na, či ji pro te in ski pro duk ti či ne slo že ne ko mu ni ka ci o ne mre že odgo vor ne za pri jem, pre nos i ko nač nu re a li za ci ju mi to ge nog signa la. Eks pan zi ja klo na ili uve ća nje će lij ske ma se, ko je se na klinič kom ni vou ma ni fe stu je kao neo pla zi ja, uslo vlje na je struk turnim i funk ci o nal nim le zi ja ma spe ci fič nih gen skih lo ku sa ko ji se na zi va ju "kan cer ski ge ni". Dve ključ ne gru pe ge na ko ji po svojim oso bi na ma za slu žu ju ovaj epi tet su: a) on ko ge ni ili mu ti rani ob li ci nor mal nih će lij skih ge na, pro to on ko ge na, ko ji se nala ze u ve ći ni euka ri ot skih ge no ma, i b) tu mor-su pre sor ski geni -an ti on ko ge ni ili in hi bi to ri ne kon tro li sa nog ra sta i pro li fera ci je će li ja, a ti me i ma lig nog fe no ti pa. Po sto je i ge ni za du že-ni za ko rek ci ju en do ge no, od no sno eg zo ge no in du ko va nih lezi ja na sled nog ma te ri ja la -tzv. DNK re per ge ni, ko ji zbog svo je funk ci je pred sta vlja ju pr vu li ni ju od bra ne in te gri te ta hu ma nog ge no ma, ali oni ne će bi ti pred met ovoga ra da [4] [5] [6] [7] .
Će lij ska ho me o sta za se odr ža va za hva lju ju ći rav no te ži ko ja po sto ji u funk ci ja ma ove dve kla se ge na. S upo red nom ak ti vaci jom on ko ge na i inak ti va ci jom tu mor-su pre sor skih ge na naru ša va se ta ho me o sta za i do la zi i do raz vo ja tu mo ra. Iz ugla sa gle da va nja me ha ni za ma pa to ge ne ze, kao i even tu al nih te rapij skih in ter ven ci ja, bit no je usta no vi ti u ko jem tre nut ku i koji se gen to kom pro ce sa ma lig ne tran sfor ma ci je ak ti vi rao, odno sno inak ti vi rao.
Onkogeni
On ko ge ni su ge ni či ji pro te in ski pro duk ti sti mu li šu rast, de obu i di fe ren ci ja ci ju će li ja po kre ta njem sig nal nog tran sduk ci onog i tran skrip ci o nog re gu la tor nog me ha ni zma (Sli ka 1). U obli ku pro to on ko ge na (nor mal ni, ne mu ti ra ni) oni se vre men ski i pro stor no stro go kon tro li sa no eks pri mi ra ju. Mu ta ci jom proto on ko ge ni pre la ze u ob lik on ko ge na, ko ji se ne kon tro li sa no
KRATAK SADRŽAJ
Oral ne skva mo ce lu lar ne kar ci no me (OSCK) od li ku je uglav nom lo ša prog no za i, upr kos po ma ci ma u te ra pij skim po stup ci ma, posled njih go di na ni je ostva ren na pre dak u pre ži vlja va nju oso ba s ovim tu mo rom. Ve li ke na de se po la žu u mo le ku lar nu me di ci nu i pro na la že nje no vih bi o lo ških mar ke ra po mo ću ko jih bi pre ci zni je ne go što to do pu šta ju kli nič ki i hi sto pa to lo ški pa ra me tri mo glo da se pred vi di po na ša nje tu mo ra. OSCK, kao i ve ći na dru gih ma lig nih obo lje nja, re zul tat su po stup ne aku mu la ci je ra zno vr snih gene tič kih i epi ge ne tič kih pro me na u će li ja ma, ko je od nor mal nih po sta ju neo pla stič ne. U ovom ra du dat je pre sek ne kih od pra vaca is tra ži va nja na po lju mo le ku lar ne bi o lo gi je oral nih kar ci no ma, s osvr tom na stu di je ko je se ba ve is pi ti va njem so mat skih mu ta cija u kan cer skim ge ni ma, uče šćem on ko ge nih vi ru sa u pa to ge ne zi i zna ča ju pro ce sa me ti la ci je za OSCK. Ta ko đe su po me nu te studi je po sve će ne utvr đi va nju even tu al nog po sto ja nja pre di spo zi ci je za raz voj OSCK.
Ključ ne re či: oral ni kar ci no mi; kan cer ski ge ni; vi ru sna in fek ci ja; hi per me ti la ci ja; pre di spo zi ci ja eks pri mi ra ju. Te mu ta ci je mo gu bi ti: tač ka ste mu ta ci je, gen ske de le ci je, am pli fi ka ci je ge na i hro mo zom ski re a ran žma ni (najče šće tran slo ka ci je).
Ne ki od on ko ge na za ko je je do ka za na ulo ga u pa to ge ne zi OSCK su H-ras, c-myc i c-erbB-2. Oni su ključ ni ak te ri u jednom od cen tral nih će lij skih sig na li za ci o nih pu te va ko ji vo de ne kon tro li sa noj pro li fe ra ci ji (Sli ka 2).
Pre ma po lo ža ju i funk ci ji, pro te in ski pro duk ti ge na fa mi li je ras (H, K, N) pri pa da ju gru pi mem bran skih G-pro te i na, ko ji či-ne pro stor no-funk ci o nal nu ve zu iz me đu re cep to ra s ko jeg prima ju mi to ge ni sig nal i ci to pla zmat skih pro tein-ki na za, na ko je ga pre no se. Po da ci o uče sta lo sti mu ta ci ja H-ras u OSCK su veo ma ša ro li ki: od 5% kod sta nov ni ka za pad nih ze ma lja do 35% kod azij skih na ro da. U na šoj po pu la ci ji uče sta lost ovih mu ta ci ja je 22% [8] , s tim da je u pod gru pi bo le sni ka s kar ci no mom vermi li o na usne taj pro ce nat još i ve ći (55%), a tu ma či se za jed nič-kim de lo va njem tri fak to ra ri zi ka: du va na, al ko ho la i UV zra če-nja [9] . Sma tra se ta ko đe da mu ta ci je u H-ras ge nu pred sta vlja ju ra ni do ga đaj u na stan ku oral nih tu mo ra i uop šte tu mo ra gla ve i vra ta, jer su za pa že ne i u od re đe nim pre kan ce ro za ma [10, 11] .
Pro te in ski pro dukt ge na c-erbB-2 je tran smem bran ski pro tein ko ji je ta ko đe uklju čen u ge ne zu pro li fe ra tiv nog sig na la od plazma-mem bra ne do je dra. Do on ko ge ne ak ti va ci je c-erbB-2 ge na naj če šće do la zi usled po ve ća nja bro ja nje go vih ko pi ja, tj. gen ske am pli fi ka ci je, ko ja za po sle di cu ima ak ti va ci ju tran smem branskog on ko pro te i na, od no sno ini ci ra nje pro li fe ra tiv nog sig na la kod iz o stan ka fak to ra ra sta. Ak ti va ci ja on ko ge na c-erbB-2 dovo di do imor ta li za ci je i tran sfor ma ci je će li ja u uslo vi ma in vitro, a utvr đe na je u mno gim tu mo ri ma. U OSCK po da ci do bije ni za al te ra ci je u c-erbB-2 ge nu, u za vi sno sti od pri me nje ne me to de, kre ću se od 20% do 80% [12, 13] . Kod na ših bo le snika sa OSCK u 45% slu ča je va usta no vlje na je mu ta ci ja c-erbB-2 ge na, i to u 32% am pli fi ka ci ja, a u 13% de le ci ja [8] . Na su mič no po ve ća nje ili sma nje nje bro ja gen skih ko pi ja uka zu je na ne stabil nost ge no ma, ko ji je klju čan fe no men u pa to ge ne zi tu mo ra [11] . Bez ob zi ra na iz ve sne opreč ne sta vo ve, ve ći na auto ra ipak sma tra da c-erbB-2 gen ostva ru je svo ju ulo gu u uz na pre do valim fa za ma bo le sti.
Eks pre si ja ge na c-myc je ta ko đe pro me nje na u ve li kom broju raz li či tih ma lig ni te ta. Pro te in ski pro dukt ovog ge na je je darni pro tein ko ji se ve zu je za DNK, ko ji mo du li ra ak tiv nost ve ćeg bro ja ge na uklju če nih u na pre do va nje će li je kroz će lij ski ci klus. Sto ga kao tran skrip ci o ni fak tor ostva ru je re gu la tor nu ak tiv nost u okvi ru va žnih pro ce sa, kao što su sti mu la ci ja pro li fe ra ci je, inhi bi ci ja di fe ren ci ja ci je i po ve ća nje ose tlji vo sti na pro a pop tot ske sti mu lu se [14] . Na osno vu po da ta ka iz li te ra tu re, usta no vlje no je da c-myc am pli fi ka ci ju po ka zu je 20-40% oral nih kar ci no ma kod lju di u ze mlja ma Evro pe i Ame ri ke (što su po da ci slič ni oni ma do bi je nim za na šu po pu la ci ju), dok je kod sta nov ni ka azij skih ze ma lja ta vred nost oko 70% [8, 15, 16] . Slič no c-erb on ko genu, i c-myc če šće mu ti ra (am pli fi ku je) u tu mo ri ma vi ših hi sto loških gra du sa, kod sla bo di fe ren ci ra nih i tu mo ra s me ta sta za ma.
Tumor-supresorski geni
Tu mor-su pre sor ski ge ni (an ti on ko ge ni) su ge ni či ji pro te in ski pro duk ti in hi bi ra ju neo pla stič nu tran sfor ma ci ju, one mo gu ća vaju ći de o bu će li ja uko li ko po sto ji ošte će nje na sled nog ma te ri jala. Uklju če ni su u kon tro lu će lij skog ci klu sa ta ko što spre ča va ju raz voj će li je kroz ci klus dok se ošte će nja ne po pra ve, a ako su ona ve li ka, do vo de do ak ti va ci je pro gra mi ra ne će lij ske smr ti (apop to ze). Mu ta ci je u tu mor-su pre sor skim ge ni ma iza zi va ju po re me ća je kon tro le će lij skog ci klu sa. Naj zna čaj ni ji gen iz ove gru pe je TP53. Odr ža va nje sta bilno sti i in te gri te ta će lij skog ge no ma je osnov na bi o lo ška funkci ja ovo ga ge na i isto i me nog pro te i na. Pre ma po da ci ma iz li tera tu re, pro tein TP53 je je dan od ključ nih tran skrip ci o nih fakto ra ili bi o mo le ku la ko ji svo jom re gu la tor nom ak tiv no šću obu zda va ju de o be će li ja s ošte će nim na sled nim ma te ri ja lom (Slika 2). To je isto vre me no i gen ko ji naj če šće mu ti ra u ve ći ni tumo ra kod lju di (go to vo kod 70% so lid nih tu mo ra) [17] . Mnoga is tra ži va nja po ka zu ju da je uče sta lost mu ta ci ja u ovom genu kod kan ce ra gla ve i vra ta oko 60% kod sta nov ni ka Evro pe i Ame ri ke, dok je znat no ma nja kod azij skih na ro da, i po ve zu je se s raz li či tim ži vot nim na vi ka ma [18] . Po da ci do bi je ni za naše bo le sni ke sa OSCK u pot pu noj su sa gla sno sti s po da ci ma iz li te ra tu re za za pad ne po pu la ci je (60%) [8, 19] . Kod na ših bole sni ka inak ti va ci ja TP53 se usled mu ta ci ja po ve ća va s na predo va njem bo le sti, pa je ta ko uče sta lost mu ta ci ja ve ća kod srednje i sla bo di fe ren ci ra nih tu mo ra (G2 i G3) u od no su na do bro di fe ren ci ra ne (G1), kao i kod in va ziv ni jih tu mo ra (T3 i T34) u od no su na ma nje in va ziv ne (T1 i T2) [20] . U ve li kom bro ju rado va iz raz li či tih de lo va sve ta ta ko đe je usta no vlje na ko re la cija iz me đu za stu plje no sti TP53 mu ta ci ja i pu še nja, ali kod naših is pi ta ni ka ta ve za ni je po tvr đe na. Sem TP53, sa OSCK se pove zu ju i pro me ne u dru gim tu mor-su pre sor skim ge ni ma, kao što su Rb i p16 [21] .
VIRUSI I PATOGENEZA OSCK
U po sled nje vre me se vi ru snim in fek ci ja ma -na ro či to in fek cija ma on ko ge nim ti po vi ma hu ma nog pa pi lo ma vi ru sa (HPV16 i HPV18), či ja je ulo ga u na stan ku kar ci no ma gr li ća ma te rice odav no po zna ta -pri pi su je po se ban zna čaj i u pa to ge ne zi OSCK. Čak se sma tra da su HPV-po zi tiv ni i HPV-ne ga tiv ni tumo ri za pra vo pot pu no raz li či ti kli nič ki en ti te ti. Bi tan me ha nizam de lo va nja HPV je taj da pro duk ti vi ru snog ge no ma, on kopro te i ni E6 i E7, inak ti vi ra ju ključ ne tu mor-su pre sor ske ge ne TP53 i Rb, što je sig nal za ne kon tro li sa nu će lij sku de o bu [21, 22] .
Eks trem na pro cen tu al na ne u jed na če nost po da ta ka iz svetske li te ra tu re o zna ča ju HPV-in fek ci ja u pa to ge ne zi OSCK na vela je is tra ži va če da pred lo že dva eti o pa to ge net ska me ha ni zma: HPV+ i HPV-. U kar ci no mi ma gla ve i vra ta u ko ji ma su usta novlje ni vi ru si mu ta ci je u tu mor-su pre sor skim ge ni ma (TP53, Rb i dr.) iz u zet no su ret ke, što zna či da je gu bi tak funk ci je tu morsu pre so ra po sle di ca in ter ak ci je s vi ru snim on ko pro te i ni ma, a ne po sle di ca mu ta ci ja u nji ho vim ge ni ma. Za ni mlji vo je da su po da ci čak i na ni vou na še po pu la ci je opreč ni. U jed noj stu di ji utvr đe na je ma la uče sta lost HPV-in fek ci ja kod OSCK u Sr bi ji i sma tra se da je če šći HPV put kan ce ro ge ne ze [8] , dok je u drugom is tra ži va nju do bi je na vi so ka uče sta lost ovih in fek ci ja [23] .
ULOGA METILACIJE
Me ti la ci ja DNK je epi ge ne tič ki me ha ni zam ne ga tiv ne re gu la cije tran skrip ci je, od no sno gen ske eks pre si je ("uti ša va nje" ge na), či ji je zna čaj u kan ce ro ge ne zi tek od ne dav no sa gle dan. Is pra van
